Free Trial

Ultralife (NASDAQ:ULBI) Stock Price Crosses Above 200 Day Moving Average - Should You Sell?

Ultralife logo with Computer and Technology background

Key Points

  • Ultralife Corporation's share price has crossed above its 200-day moving average of $6.56, reaching a high of $7.18 during trading, with shares last priced at $6.93.
  • Wall Street analysts have upgraded Ultralife's stock from a "buy" to a "strong-buy" rating, with an average price target of $14.00.
  • In recent insider trading, Director Bradford T. Whitmore purchased 29,766 shares at $6.63 each, boosting his ownership stake to over 1.1 million shares.
  • Interested in Ultralife? Here are five stocks we like better.

Ultralife Corporation (NASDAQ:ULBI - Get Free Report)'s stock price passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $6.56 and traded as high as $7.18. Ultralife shares last traded at $6.93, with a volume of 57,953 shares.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen raised shares of Ultralife from a "buy" rating to a "strong-buy" rating in a research note on Friday, June 6th. One investment analyst has rated the stock with a Buy rating, Based on data from MarketBeat, the company has an average rating of "Buy" and a consensus price target of $14.00.

Check Out Our Latest Analysis on ULBI

Ultralife Stock Performance

The company has a current ratio of 3.31, a quick ratio of 1.62 and a debt-to-equity ratio of 0.34. The business's 50 day moving average is $7.96 and its 200 day moving average is $6.54. The stock has a market capitalization of $115.65 million, a PE ratio of 36.58 and a beta of 1.08.

Ultralife (NASDAQ:ULBI - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The technology company reported $0.07 EPS for the quarter, missing analysts' consensus estimates of $0.14 by ($0.07). Ultralife had a return on equity of 2.68% and a net margin of 1.79%.The firm had revenue of $48.56 million for the quarter, compared to analysts' expectations of $51.00 million.

Insiders Place Their Bets

In related news, Director Bradford T. Whitmore acquired 29,766 shares of the firm's stock in a transaction that occurred on Thursday, August 21st. The stock was bought at an average price of $6.63 per share, for a total transaction of $197,348.58. Following the acquisition, the director directly owned 1,128,731 shares of the company's stock, valued at $7,483,486.53. This represents a 2.71% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. In the last three months, insiders have bought 58,664 shares of company stock worth $387,049. Company insiders own 40.00% of the company's stock.

Institutional Investors Weigh In On Ultralife

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ULBI. Raymond James Financial Inc. bought a new stake in Ultralife during the 4th quarter valued at about $522,000. Barclays PLC lifted its holdings in Ultralife by 13.7% during the 4th quarter. Barclays PLC now owns 15,233 shares of the technology company's stock valued at $113,000 after buying an additional 1,838 shares in the last quarter. Marshall Wace LLP lifted its holdings in Ultralife by 11.6% during the 4th quarter. Marshall Wace LLP now owns 32,885 shares of the technology company's stock valued at $245,000 after buying an additional 3,426 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in Ultralife by 0.7% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,053,613 shares of the technology company's stock valued at $7,849,000 after buying an additional 7,174 shares in the last quarter. Finally, Northern Trust Corp lifted its holdings in Ultralife by 8.0% during the 4th quarter. Northern Trust Corp now owns 87,633 shares of the technology company's stock valued at $653,000 after buying an additional 6,484 shares in the last quarter. Institutional investors own 30.68% of the company's stock.

About Ultralife

(Get Free Report)

Ultralife Corporation, together with its subsidiaries, designs, manufactures, installs, and maintains power, and communication and electronics systems worldwide. The company operates in two segments, Battery & Energy Products and Communications Systems. The Battery & Energy Products segment offers lithium 9-volt, cylindrical, thin lithium manganese dioxide, rechargeable, and other non-rechargeable batteries; lithium-ion cells, multi-kilowatt module lithium-ion battery systems, and uninterruptable power supplies; and rugged military and commercial battery charging systems and accessories, including smart chargers, multi-bay charging systems, and various cables.

Read More

Should You Invest $1,000 in Ultralife Right Now?

Before you consider Ultralife, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ultralife wasn't on the list.

While Ultralife currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report
Like this article? Share it with a colleague.